EMA/793134/2017

European Medicines Agency decision

P/0396/2017

of 19 December 2017

on the agreement of a paediatric investigation plan and on the granting of a waiver for trazodone (hydrochloride) (Trittico and associated names), (EMEA-002142-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0396/2017

of 19 December 2017

on the agreement of a paediatric investigation plan and on the granting of a waiver for trazodone (hydrochloride) (Trittico and associated names), (EMEA-002142-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A on 12 February 2017 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 November 2017, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for trazodone (hydrochloride) (Trittico and associated names), age-appropriate oral liquid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for trazodone (hydrochloride) (Trittico and associated names), age-appropriate oral liquid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A, Viale Amelia 70, 00181 – Rome, Italy.

EMA/PDCO/534529/2017
London, 10 November 2017

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMEA-002142-PIP01-17

Scope of the application

Active substance(s):

Trazodone (hydrochloride)

Invented name:

Trittico and associated names

Condition(s):

Treatment of insomnia

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Age-appropriate oral liquid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A submitted for agreement to the European Medicines Agency on 12 February 2017 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 21 March 2017.

Supplementary information was provided by the applicant on 8 August 2017. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of insomnia

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- age-appropriate oral liquid dosage form for oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Treatment of insomnia

2.1.1. Indication(s) targeted by the PIP

Treatment of insomnia in children and adolescents with neurodevelopmental disorders

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Age-appropriate oral liquid dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	**Study 1:** Development of a 3% formulation of trazodone oral drops, for administration to paediatric patients from 6 to less than 18 years of age **Study 2:** Development of a 1.5% formulation of trazodone oral drops, for administration to paediatric patients from 2 to less than 6 years of age
Non-clinical studies	1	**Study 3:** Definitive juvenile toxicity study in rats

Clinical studies	2	**Study 4:** Multi-centre, randomised, single blind, single and repeated-doses PK/PD study **Study 5:** 12-week randomised, double blind, placebo controlled study to evaluate the efficacy and safety of trazodone to treat insomnia in children and adolescents with neurodevelopmental disorders
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use	No
Date of completion of the paediatric investigation plan:	By November 2022
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

Authorised indication(s):

- Depressive disorders with or without anxiety
- Supportive treatment of pain
- Enhancement of anaesthesia

Authorised pharmaceutical form(s):

Film-coated tablets

Prolonged-release tablets

Oral drops, solution

Solution for injection

Authorised route(s) of administration:

Oral use

Intramuscular use

Intravenous use